VOGO joins “Tech 40” index and receives “European Rising Tech” label

Euronext awards VOGO

VOGO is pleased to announce today its admission to the “Tech 40” index. Moreover, the Group is recognized by Euronext by obtaining the “European Rising Tech” label.

Integration of the “Tech 40” Euronext index

Less than two years after its IPO, VOGO enters the “Tech 40” index. Launched in 2015 by Euronext, this index distinguishes the 40 best performing young technology stocks according to economic, financial and stockmarket criteria from a panel of nearly 300 SMEs listed on the Euronext markets in Amsterdam, Brussels, Dublin, Lisbon and Paris and operating in the life sciences, eco-industries or the TMT (Technologies, Media and Telecommunications) sectors.

Award with the “European Rising Tech” label

In addition, Euronext awards VOGO the “European Rising Tech” label, which recognizes 98 particularly successful companies from a universe of more than 350 small and medium-sized market capitalizations listed on the Euronext markets and from the technology sector.

Recognition and visibility

Christophe Carniel, Chairman & Chief Executive Officer of VOGO, says:

“We are proud to receive these two distinctions which highlight the good performance of the Group, less than 2 years after our IPO. VOGO’s admission to the ‘Tech40’ index rewards the efforts and the commitment that have been shown by our teams to launch new innovative offers particularly in Health with EasyCov. This will also contribute to raise further our profile among investors.”

Category: Latest news

Share this article:

Other related articles

  • Researchers from CNRS, Sys2Diag laboratories get equipped with VOKKERO GUARDIAN

    The collaboration of VOGO and Sys2Diag did not end with the EasyCov project. When researchers at the famous research laboratory learned about the functionality and performance of the VOKKERO GUARDIAN systems marketed by VOGO, they immediately understood how much help they could give them in many of their daily tasks. The example of the clinical study…